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Abstract 32 
Objectives 33 
To evaluate serum AMH levels in polycystic ovary syndrome (PCOS) and in its different 34 
phenotypes in relation to clinical, endocrine and metabolic parameters using a new automated 35 
VIDAS® method and to compare it with the Gen II method.  36 
Study design 37 
Multi-centre study including 319 PCOS women and 109 healthy controls.  38 
Results  39 
Serum AMH levels measured using VIDAS® were significantly higher in PCOS women than 40 
controls (p<0.001), and they correlated with those measured using the AMH Gen II method. 41 
An AMH cut-off value of 42.1pmol/L distinguished PCOS women from controls with 67% 42 
sensitivity and 83% specificity. The PCOS women with three Rotterdam criteria or 43 
hyperandrogenism displayed significantly higher AMH levels compared with those with two 44 
Rotterdam criteria or normoandrogenism. In PCOS, AMH levels correlated positively with 45 
luteinizing hormone (LH), androgen and sex hormone-binding globulin (SHBG) levels and 46 
negatively with BMI, abdominal obesity, follicle-stimulating hormone (FSH), fasting glucose 47 
and insulin, and insulin resistance.  48 
Conclusions 49 
AMH evaluated using the VIDAS® method distinguished PCOS patients from healthy 50 
controls relatively well, especially in those with more severe phenotypes. Further studies are 51 
needed to establish whether AMH measurements can distinguish PCOS patients with different 52 
metabolic risk factors. 53 
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Introduction 56 
Polycystic ovary syndrome (PCOS) is characterized by oligoamenorrhoea (OA), 57 
hyperandrogenism (HA) and polycystic ovary morphology (PCOM) on ultrasound (1,2). The 58 
diagnosis of the syndrome requires the presence of at least two of the three aforementioned 59 
criteria (3, 4). 60 
AMH is a member of the transforming growth factor-beta superfamily produced by the 61 
ovarian granulosa cells (5). The main physiological roles of AMH in the ovary are the 62 
prevention of primordial follicles recruitment and the modulation of FSH action in early 63 
follicular development (6,7). Serum AMH levels are correlated with the ovarian antral follicle 64 
count (AFC) in women with and without PCOS (8,9). As AMH levels are strongly correlated 65 
with both biochemical HA and AFC, studies have suggested that AMH levels could be used 66 
as a surrogate tool of PCOM in the diagnosis of PCOS (10,11). However, AMH assays lack 67 
an international standard, and concentrations and cut-off values are method dependent.  68 
The presence of relatively high AMH levels in the peripheral circulation suggests that 69 
circulating AMH may have also a function outside the reproductive system. Low AMH levels 70 
could be associated with cardiovascular disease and metabolic disorders (12) whereas 71 
elevated AMH levels seem to be related to PCOS severity (13,14,15,16,17,18). 72 
In a population study of Nordic Caucasian women, our first objective was to evaluate serum 73 
AMH levels and their diagnostic value in PCOS using the VIDAS® (bioMérieux SA, Marcy-74 
l’Etoile, France) kit. Our second aim was to examine the correlation of serum AMH levels 75 
measured with this kit with those obtained using the AMH Gen II enzyme-linked 76 
immunosorbent assay (ELISA) (Beckman Coulter, Inc., CA, USA). A formal comparison 77 
between VIDAS® and Gen II methods has not been published before, but both methods have 78 
been recently compared with Elecsys® (Roche Diagnostics) (19,20). 79 
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In addition, in PCOS patients, we investigated serum levels of AMH in different phenotypes 80 
of the syndrome, as well as the association of AMH levels with AFC, and with hormonal and 81 
metabolic parameters.  82 
Materials and methods 83 
Subjects 84 
The PCOS (n = 319) group had been originally recruited to a randomized controlled study 85 
investigating the efficacy of metformin in the treatment of anovulatory infertility (21). The 86 
inclusion and the exclusion criteria have been reported earlier (21).  87 
Hyperandrogenism (HA) was defined as clinical, defined as a Ferriman–Gallwey score>7 or 88 
biochemical, defined as a testosterone level ≥+2SD (i.e. ≥2.3nmol/L). The PCOS patients 89 
were divided further into four phenotypes according to the Rotterdam diagnosis criteria: 90 
A:PCOM+HA+OA (n = 106), B:HA+OA (n = 18), C:HA+PCOM (n = 12) and D:OA+PCOM 91 
(n = 124) (3).  92 
The control subjects consisted of 96 healthy Caucasian women (18–39 years; BMI:19-93 
35kg/m2) recruited from the community by advertisements in local newspapers (22,23). All 94 
were non-smokers and none of them used any hormonal contraception or other hormonal 95 
preparations, had regular menstrual cycles, and none had hirsutism/hyperandrogenaemia or 96 
were using any medications.  97 
After an overnight fast, serum samples were obtained in the follicular phase 1–7 days after 98 
spontaneous menstruation (oligomenorrhoeic PCOS patients and controls) or at a convenient 99 
time (amenorrhoeic PCOS women) during 2004–2009 and were immediately frozen at -20°C. 100 
Laboratory and clinical measurements  101 
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AMH concentrations and serum levels of LH, FSH and estradiol (E2) were measured in the 102 
stored samples using the VIDAS® automated enzyme immunoassay with fluorescent 103 
detection (bioMérieux). The measuring range for AMH was 0.14–64.3pmol/L (0.02–104 
9.00ng/mL), and the intra-assay coefficient of variation was 5.15%. For concentrations over 105 
64.3pmol/L (9ng/mL), a dilution procedure was used. A detailed description of this new 106 
automated method has been published recently (21).  107 
In women with PCOS, the determinations of AMH had been also performed earlier with the 108 
AMH Gen II enzyme linked immunosorbent assay (Beckman Coulter).  109 
 110 
Waist and hip circumference, serum levels of glucose, insulin, testosterone and SHBG, and 111 
calculation of the free androgen index (FAI), homeostasis model assessment-estimated insulin 112 
resistance index (HOMA-IR) and the areas under the curve for incremental insulin and 113 
glucose were measured as reported earlier (21). 114 
 115 
Statistical analyses 116 
An independent sample Student’s t-test was used for continuous variables if their distributions 117 
were not skewed. Correlations between variables were analysed by Spearman’s correlation 118 
test. A receiver operating characteristic (ROC) curve analysis was used to determine the best 119 
cut-off point for AMH to distinguish PCOS women from controls. Intraclass correlation 120 
coefficient and its 95% confidence interval between AMH values measured with VIDAS® 121 
and Gen II method was calculated based on mean-rating (k=3), consistency, 2-way mixed-122 
effects model. Statistical analyses were performed using IBM SPSS Statistics 20.0 (SPSS, 123 
Inc., IBM Corp, New York, USA.). A p-value <0.05 was considered statistically significant. 124 
Results 125 
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Anthropometric, metabolic and hormonal parameters of the women with PCOS and the 126 
controls are presented in Table 1. 127 
 128 
Serum AMH concentrations in the PCOS patients and controls 129 
The serum levels of AMH were significantly higher in the PCOS women than in controls 130 
(66.1±47.4pmol/L vs. 30.7±17.4pmol/L, p<0.001, Figure 1a), and the levels correlated 131 
significantly with AFCs (r=0.58, p<0.001).  132 
The sensitivity and specificity of the serum concentration of AMH in distinguishing PCOS 133 
women from controls were evaluated using cut-off values according to the ROC curve. The 134 
best combined sensitivity (67%) and specificity (83%) was obtained using an AMH cut-off 135 
value of 42.1pmol/L with the VIDAS® kit (Figure 2a).  136 
Comparison of serum AMH concentrations between the VIDAS® and Gen II ELISA 137 
methods  138 
In the PCOS group, the mean AMH serum level was 66.1±47.4pmol/L with the VIDAS® and 139 
58.9±33.9pmol/L with the AMH Gen II method. Intraclass correlation coefficient value 140 
(0.927 (95% confidence interval 0.909 – 0.941)) indicated an excellent level of reliability.  141 
Serum AMH concentrations according to PCOS phenotypes 142 
PCOS women with the phenotype A had significantly higher serum AMH and testosterone 143 
levels as compared with those of PCOS women who fulfilled only two of the Rotterdam 144 
criteria (phenotypes B/C/D) (Table 1, Figure 1b). In addition, PCOS women with phenotype 145 
A (91.7±61.9pmol/L) had significantly higher serum AMH levels than those with phenotype 146 
B (43.6±17.4pmol/L, p<0.001) or D (61.0±33.3pmol/L, p<0.001). An AMH cut-off value of 147 
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49.0pmol/L showed sensitivity of 79% and specificity of 92% in distinguishing PCOS women 148 
with the phenotype A from controls (Figure 2b).  149 
Serum levels of AMH and E2 and the BMI values were significantly higher in 150 
hyperandrogenic (A/B/C) PCOS phenotypes as compared with the normoandrogenic (D) 151 
phenotype (Table 1, Figure 1c). An AMH cut-off value of 49.0pmol/L displayed a sensitivity 152 
of 71% and a specificity of 92% in distinguishing hyperandrogenic PCOS women from 153 
controls (Figure 2c) and a cut-off value of 42.4pmol/L had a sensitivity of 66% and specificity 154 
of 83% in distinguishing phenotype D (normoandrogenic phenotype) from controls. 155 
Serum AMH concentrations and hormonal and metabolic parameters 156 
In the PCOS group, there was a statistically significant positive correlation between AMH and 157 
AFC (r=0.58,p<0.001), SHBG (r=0.18,p=0.002), testosterone (r=0.49,p<0.001), FAI 158 
(r=0.20,p<0.001) and LH (r=0.32,p<0.001) and a statistically significant negative correlation 159 
between AMH and BMI (r=-0.26,p<0.001), waist circumference (r=-0.23,p<0.001), waist-160 
hip-ratio (r=-0.13,p=0.028), fasting glucose (r=-0.12,p=0.039), fasting insulin (r=-161 
0.27,p<0.001), AUC insulin (r=-0.14,p=0.017), HOMA-IR (r=-0.26,p<0.001) and FSH (r=-162 
0.13,p=0.026).  163 
The serum AMH levels of normal weight PCOS women (BMI<25kg/m2) were significantly 164 
higher than those of overweight PCOS women (BMI>25kg/m2: 75.7±54.1pmol/L vs. 165 
58.1±39.0pmol/L, p=0.001) or obese PCOS women (BMI >30kg/m2: 52.1±35.0pmol/L, 166 
p<0.001).  167 
 168 
 169 
 170 
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Discussion 171 
In this study, we report higher AMH levels for PCOS women compared to controls and 172 
several AMH cut-off values for PCOS phenotypes to distinguish them from controls. 173 
Moreover, in women with PCOS, serum AMH levels correlated positively with SHBG, 174 
androgen and LH levels and negatively with obesity, fasting glucose and insulin, and insulin 175 
resistance.  176 
The results obtained in the present study using the VIDAS® method are in line with those of 177 
previous studies, showing higher mean serum AMH levels in women with PCOS than in 178 
controls and a significant correlation between AMH and AFC (16,24,25,26,27,28,29). 179 
Importantly, the differences in serum AMH values between PCOS women and controls were 180 
significant even though the women in the control group were slightly younger than the 181 
women with PCOS. The best cut-off value (42.1pmol/L) to distinguish PCOS patients from 182 
controls was similar to that reported in some studies (30,31) but lower than that found in some 183 
other studies (28,29), with 67% sensitivity and 83% specificity. Importantly, serum AMH 184 
levels determined by the VIDAS® method were strongly and positively correlated with those 185 
measured earlier using the AMH Gen II method. Some of the samples in the present study had 186 
been frozen for a mean time of ten years before measurements with VIDAS assay, pointing to 187 
good reliability of the method and stability of the samples.  188 
In PCOS women there was a positive correlation between serum levels of AMH and those of 189 
testosterone, LH and FAI, in line with the results of previous studies 190 
(27,29,32,33,34,35,36,37) and pointing to an interaction between AMH, LH and androgen 191 
secretion. Such an interaction may contribute to the pathogenesis of PCOS (38), as 192 
demonstrated by a previous study, which reported increased gonadotropin-releasing hormone 193 
(GnRH)-dependent pulsatility and LH surges through GnRH- neurone AMH receptor 194 
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activation in mice (39). In the present study, hyperandrogenic PCOS phenotypes displayed 195 
significantly higher AMH levels as compared with those in normoandrogenic phenotypes. 196 
Moreover, the phenotype A (full-blown syndrome) expressed higher levels than the 197 
phenotypes including only two Rotterdam criteria. Again, these findings are in agreement 198 
with that of previous studies, which showed that women with more severe PCOS 199 
manifestations exhibited elevated serum AMH levels (13,14,15,16,17,18). Of note, AMH was 200 
able to distinguish hyperandrogenic and phenotype A PCOS patients from controls with the 201 
best sensitivity and specificity. Whether hyperandrogenism itself induces enhanced AMH 202 
production remains unresolved and could not be clarified in the present study design. 203 
Women with PCOS are known to present with an altered metabolic profile, characterized by 204 
abdominal obesity, insulin resistance, metabolic syndrome and an elevated risk of type 2-205 
diabetes (40,41,42). In the present study, in accordance with the findings of some (37,43) but 206 
not all (38,44) studies, we found negative correlations between serum AMH levels, BMI and 207 
several metabolic risk factors. Moreover, in the PCOS group, AMH levels were significantly 208 
higher in women of normal weight as compared with those of overweight women 209 
(BMI>25kg/m2), and the difference was even greater when we compared the normal weight 210 
and obese group (BMI>30kg/m2). Interestingly, low AMH levels have been associated with 211 
an elevated risk of metabolic syndrome in PCOS (45) and with an increased risk of 212 
cardiovascular disease in non-PCOS women (12). The negative correlations between AMH 213 
and metabolic parameters could be driven by obesity, as the significance disappeared in a 214 
multivariate regression analysis including BMI (37,43). On the other hand, in another study, 215 
the hyperandrogenic phenotypes of PCOS with the highest AMH concentrations display the 216 
most unfavourable metabolic profile (46). Likewise, in the present study, the group with full-217 
blown PCOS had higher serum levels of AMH and testosterone, and greater FAI values as 218 
compared with the group fulfilling only two Rotterdam criteria. However, there were no 219 
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differences in anthropometric or metabolic parameters between these groups. Further studies 220 
are therefore needed to clarify the nature of the complex relationship between AMH levels, 221 
hyperandrogenism and metabolic risk factors in humans. 222 
Strengths and limitations 223 
The strengths of this study are the homogenous study population, which included only Nordic 224 
Caucasian women and the well-defined patient and control groups. As for limitations of the 225 
study, the control group and some of the PCOS phenotypic subgroups included a relatively 226 
low number of participants. In addition, as we did not measure AMH levels in the control 227 
group using the AMH Gen II, we were not able to compare the sensitivity and specificity of 228 
the two methods to distinguish PCOS from controls. Furthermore, the study population was 229 
not population based but consisted of women who had visited an infertility clinic. These 230 
women probably had more severe PCOS. Given, that the control group did not include 231 
women with any PCOS symptoms, namely isolated hyperandrogenism or oligoamenorrhea, 232 
this could result into higher differences in the serum levels of AMH between the two study 233 
groups. Last, the serum samples had been stored for 6–11 years and had gone through at least 234 
one previous freeze-thaw cycle. This may have affected the reliability of some laboratory 235 
determinations.  236 
Conclusion 237 
In conclusion, AMH concentrations measured with the VIDAS® method correlated well with 238 
those measured using the AMH Gen II method and were able to distinguish women with 239 
PCOS from healthy controls with 67% sensitivity and 83% specificity. Moreover, serum 240 
AMH correlated positively with hyperandrogenism and negatively with unfavourable 241 
metabolic factors, underlining the close relation of AMH with pivotal pathogenic factors of 242 
PCOS. Further studies are needed to clarify the nature of the complex relationship between 243 
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AMH levels and the risk of metabolic disorders and to establish whether AMH levels may 244 
serve as a useful tool to distinguish PCOS patients with different metabolic risk factors. 245 
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Figure legends 255 
 256 
Figure 1: Box-plots show serum AMH concentrations in all PCOS women and controls (A), 257 
in PCOS patients with three Rotterdam criteria and two Rotterdam criteria (B) and in the 258 
hyperandrogenic and normoandrogenic phenotypes of PCOS (C). P-values according to the 259 
independent sample t-test. AMH serum levels are measured by the bioMerieux VIDAS® 260 
method. 261 
Figure 2:  Receiver operating characteristic-curves show the best cut-off values of serum 262 
AMH levels between PCOS and controls (A), phenotype A of PCOS and controls (B) and 263 
hyperandrogenic PCOS and controls (C). Cut-off points with the best-combined sensitivity 264 
and specificity are shown in the Figure. AMH serum levels are measured by the bioMerieux 265 
VIDAS® method. 266 
Abbreviations: PCOS, polycystic ovary syndrome; AMH, Anti-Müllerian hormone;  267 
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Table 1. Anthropometric, metabolic and hormonal parameters in all PCOS patients and in different PCOS subgroups. P-values according to the 
independent sample t-test.  
1 Comparisons between all PCOS women and controls. 
2 Comparisons between PCOS three-criteria and PCOS two-criteria. 
3 Comparisons between hyperandrogenic PCOS group and normoandrogenic PCOS group. 
Abbreviations: BMI, Body mass index; AFC, Antral follicle count; AUC, Area under curve; HOMA-IR, Homeostatic Model Assessment of 
Insulin Resistance; FSH, Follicle-stimulating hormone; LH, Luteinizing hormone; E2, Estradiol; T, Testosterone; SHBG, Sex hormone-binding 
globulin; FAI, Free androgen index; AMH, Anti-Müllerian hormone.  
 
 
 
 
 
 
 
 
 
 All PCOS 
women 
(n=319) 
Controls 
(n=96) 
p-value1 PCOS 3-
criteria 
(n=106) 
PCOS 2-
criteria 
(n=154) 
p-value2 Hyperandrogenic 
PCOS (n=136) 
Normoandroge
nic PCOS 
(n=124) 
p-value3 
Age (yr) 28.1 ± 4.3 26.0 ± 5.2 <0.001 28.3 ± 3.7 28.1 ± 4.3 ns (0.7) 28.2 ± 3.9 28.1 ± 4.3 ns (0.8) 
BMI (kg/m2) 27.3 ± 6.3 22.8 ± 3.6 <0.001 27.5 ± 6.2 26.9 ± 6.5 ns (0.4) 28.0 ± 6.5 26.2 ± 6.2 0.024 
Waist (cm) 85.0 ± 15.0   85.8 ± 15.3 84.1 ± 15.1 ns (0.4) 86.6 ± 15.8 82.7 ± 14.3 0.042 
Waist-hip-ratio 0.8 ± 0.1   0.8 ± 0.1 0.8 ± 0.1 ns (0.3) 0.8 ± 0.1 0.8 ± 0.1 ns (0.1) 
AFC 23.4 ± 6.7   26.5 ± 7.3 23.4 ± 5.1 <0.001 25.1 ± 7.4 24.2 ± 4.8 ns (0.3) 
Fasting glucose  
(mmol/L) 
5.1 ± 0.5   5.1 ± 0.4 5.1 ± 0.4 ns (0.5) 5.1 ± 0.4 5.0 ± 0.5 ns (0.5) 
Fasting insulin  
(mU/L)  
11.2 ± 11.5   10.4 ± 7.9 11.9 ± 13.5 ns (0.3) 11.5 ± 10.6 11.0 ± 12.6 ns (0.7) 
AUCgluc 767.4 ± 167.5   784.9 ± 180.4 757.8 ± 160.6 ns (0.2) 785.4 ± 173.2 750.6 ± 163.4 ns (0.1) 
AUCins  8412.7 ±  
6937.2 
  9243.9± 
7602.9 
8116.6 ± 
6755.4 
ns (0.2) 9179.3 ± 7409.0 7924.9 ±  
6766.6 
ns (0.2) 
HOMA-IR 2.6 ± 2.8   2.4 ± 1.9 2.8 ± 3.3 ns (0.3) 2.6 ± 2.5 2.6 ± 3.2 ns (0.9) 
FSH (mIU/mL) 6.2 ± 2.1 5.7 ± 2.1 ns (0.05) 6.1 ± 1.9 6.3 ± 2.0 ns (0.5) 6.1 ± 1.9 6.3 ± 1.9 ns (0.4) 
LH (mIU/mL) 6.9 ± 4.8 3.3 ± 1.6 <0.001 7.6 ± 3.9 6.7 ± 5.1 ns (0.1) 7.5 ± 4.7 6.6 ± 4.6 ns (0.1) 
E2 (pmol/L) 268.5 ± 207.9 155.9 ± 74.4 <0.001 296.3 ± 193.1 268.7 ± 234.1 ns (0.3) 309.3 ± 238.8 248.2 ± 189.7 0.024 
T  (nmol/L) 1.6 ± 0.7   2.0 ± 0.7 1.4 ± 0.5 <0.001 2.0 ± 0.7 1.3 ± 0.4 <0.001 
SHBG (nmol/L) 50.9 ± 27.7   51.8 ± 26.7 51.6 ± 29.9 ns (0.9) 51.5 ± 26.9 51.8 ± 30.4 ns (0.9) 
FAI 3.8 ± 2.5   4.8 ± 2.7 3.5 ± 2.3 <0.001 4.7 ± 2.6 3.4 ± 2.3 <0.001 
AMH VIDAS  
(pmol/L) 
66.1± 47.4 30.7 ± 17.4 <0.001 91.7 ± 61.9 58.6 ± 32.5 <0.001 82.3 ± 58.8 61.0 ± 33.3 <0.001 


